DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–53.

Article  PubMed  CAS  Google Scholar 

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human-breast cancer - correlation of relapse and survival with amplification of the Her-2 Neu oncogene. Science. 1987;235:177–82.

Article  PubMed  CAS  Google Scholar 

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

Article  PubMed  CAS  Google Scholar 

Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–75.

Article  PubMed  CAS  Google Scholar 

Chen LP, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–42.

Article  PubMed  PubMed Central  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

Article  PubMed  PubMed Central  CAS  Google Scholar 

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.

Article  PubMed  CAS  Google Scholar 

Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651–9.

Article  PubMed  CAS  Google Scholar 

Jafari M, Kadkhodazadeh M, Shapourabadi MB, Goradel NH, Shokrgozar MA, Arashkia A, et al. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Front Immunol. 2022;13:1012806.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sanjuán R, Garijo R, Hernández P, Rivas C, Diallo JS. Experimental evolution of a p53-specific oncolytic vesicular stomatitis virus. Hum Gene Ther. 2014;25:A22–A22.

Google Scholar 

Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008;15:877–84.

Article  PubMed  CAS  Google Scholar 

Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Phillips MB, Stuart JD, Stewart RMR, Berry JTL, Mainou BA, Boehme KW. Current understanding of reovirus oncolysis mechanisms. Oncolytic Virotherapy. 2018;7:53–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers. 2020. https://doi.org/10.3390/cancers12113219.

Article  PubMed  PubMed Central  Google Scholar 

Zhao YQ, Liu ZM, Li L, Wu J, Zhang HB, Zhang HH, et al. Oncolytic adenovirus: prospects for cancer immunotherapy. Front Microbiol. 2021;12:707290.

Article  PubMed  PubMed Central  Google Scholar 

Bramante S, Kaufmann JK, Veckman V, Nettelbeck DM, Hemminki O, Liikanen I, et al. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Cancer Immunol Res. 2015;3:1775–83.

Article  Google Scholar 

Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18:1874–84.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rojas JJ, Thorne SH. Theranostic potential of oncolytic vaccinia virus. Theranostics. 2012;2:363–73.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, et al. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol. 2002;76:10951–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mauser A, Holley-Guthrie E, Zanation A, Yarborough W, Kaufmann W, Klingelhutz A, et al. The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F–1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. J Virol. 2002;76:12543–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen C, Yue D, Lei L, Wang H, Lu J, Zhou Y, et al. Promoter-operating targeted expression of gene therapy in cancer: current stage and prospect. Mol Ther Nucleic Acids. 2018;11:508–14.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yano S, Tazawa H, Kishimoto H, Kagawa S, Fujiwara T, Hoffman RM. Real-time fluorescence image-guided oncolytic virotherapy for precise cancer treatment. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22020879.

Article  PubMed  PubMed Central  Google Scholar 

Kim H, Choi H, Lee SK. Epstein-Barr virus microRNA miR-BART20-5p suppresses lytic induction by inhibiting BAD-mediated caspase-3-dependent apoptosis. J Virol. 2016;90:1359–68.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, Chiang AK. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer. 2012;131:1930–40.

Article  PubMed  CAS  Google Scholar 

Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 2004;10:5299–312.

Article  PubMed  CAS  Google Scholar 

Hagemeier SR, Barlow EA, Meng Q, Kenney SC. The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J Virol. 2012;86:13360–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin. 2009;30:467–77.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Saari H, Lazaro-Ibanez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release. 2015;220:727–37.

Article  PubMed  CAS  Google Scholar 

Thoidingjam S, Sriramulu S, Freytag S, Brown SL, Kim JH, Chetty IJ, et al. Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. Transl Med Commun. 2023;8:11.

Article  PubMed  PubMed Central  Google Scholar